Slideshow

New FDA Warning

Author(s):

James Phelps, MD

A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.

Related Videos
bipolar
bipolar
bipolar
journey
Related Content
bipolar
March 4th 2025

BHV-7000 for Bipolar Disorder Fails in Phase 2/3 Trial

Leah Kuntz
Blue Light, Depression, and Bipolar Disorder
August 4th 2021

Blue Light, Depression, and Bipolar Disorder

Chris Aiken, MD Kellie Newsome, PMH-NP
bipolar
February 25th 2025

FDA Accepts sNDA for Uzedy Extended-Release Injectable Suspension for Bipolar I Disorder

Leah Kuntz
Four Myths About Lamotrigine
August 3rd 2021

Four Myths About Lamotrigine

Chris Aiken, MD Kellie Newsome, PMH-NP
mania
February 19th 2025

Mania and Hypomania: Latest Thinking on Diagnosis and Duration of Episodes

David N. Osser, MD
Largest Genetic Study of Bipolar Disorder Identifies 298 Regions of the Genome That Increase Risk for the Condition
February 16th 2025

Largest Genetic Study of Bipolar Disorder Identifies 298 Regions of the Genome That Increase Risk for the Condition

Elizabeth Dowling
© 2025 MJH Life Sciences

All rights reserved.